372 filings
Page 3 of 19
4
NRXP
NRX Pharmaceuticals Inc
24 Aug 23
NRX Pharmaceuticals / Jonathan C Javitt ownership change
12:14pm
4
NRXP
NRX Pharmaceuticals Inc
23 Aug 23
NRX Pharmaceuticals / Jonathan C Javitt ownership change
9:24am
8-K
NRXP
NRX Pharmaceuticals Inc
14 Aug 23
Entry into a Material Definitive Agreement
5:10pm
424B5
NRXP
NRX Pharmaceuticals Inc
14 Aug 23
Prospectus supplement for primary offering
5:06pm
10-Q
2023 Q2
NRXP
NRX Pharmaceuticals Inc
Quarterly report
14 Aug 23
4:34pm
8-K
NRXP
NRX Pharmaceuticals Inc
28 Jul 23
Entry into a Material Definitive Agreement
5:15pm
424B5
NRXP
NRX Pharmaceuticals Inc
8 Jun 23
Prospectus supplement for primary offering
10:21am
8-K/A
NRXP
NRX Pharmaceuticals Inc
7 Jun 23
NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering
5:18pm
8-K
NRXP
NRX Pharmaceuticals Inc
6 Jun 23
NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering
4:27pm
8-K
NRXP
NRX Pharmaceuticals Inc
5 Jun 23
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101
8:00am
10-K/A
2022 FY
NRXP
NRX Pharmaceuticals Inc
Annual report (amended)
26 May 23
5:00pm
10-Q
2023 Q1
NRXP
NRX Pharmaceuticals Inc
Quarterly report
15 May 23
5:04pm
8-K
NRXP
NRX Pharmaceuticals Inc
21 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
NRXP
NRX Pharmaceuticals Inc
31 Mar 23
NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update
6:30am
10-K
2022 FY
NRXP
NRX Pharmaceuticals Inc
Annual report
31 Mar 23
12:00am
424B5
NRXP
NRX Pharmaceuticals Inc
14 Mar 23
Prospectus supplement for primary offering
6:47am
8-K/A
NRXP
NRX Pharmaceuticals Inc
14 Mar 23
NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering
6:45am
8-K
NRXP
NRX Pharmaceuticals Inc
13 Mar 23
Regulation FD Disclosure
6:45am
424B5
NRXP
NRX Pharmaceuticals Inc
10 Mar 23
Prospectus supplement for primary offering
4:17pm